Biological and genetic characterization of a human immunodeficiency virus strain resistant to CXCR4 antagonist T134 - PubMed (original) (raw)

Biological and genetic characterization of a human immunodeficiency virus strain resistant to CXCR4 antagonist T134

K Kanbara et al. AIDS Res Hum Retroviruses. 2001.

Abstract

The chemokine receptors CXCR4 and CCR5 are considered to be potential targets for the inhibition of HIV-1 replication. We have reported that T134 and T140 inhibited X4 HIV-1 infection specifically because they acted as CXCR4 antagonists. In the present study, we have generated a T134-resistant virus (trHIV-1(NL4-3)) in a cell culture with gradually increasing concentrations of the compound. The EC(50) of T134 against trHIV-1(NL4-3) recovered after 145 passages was 15 times greater than that against wild-type HIV-1(NL4-3). This adapted virus was resistant to other CXCR4 antagonists, T140, AMD3100, and ALX40-4C, and SDF-1; from 10 to 145 times greater than that against wild-type HIV-1(NL4-3). On the other hand, T134, T140, and ALX40-4C were still active against AMD3100-resistant viruses (arHIV-1(018A)). The trHIV-1(NL4-3) contained the following mutations in the V3 loop of gp120: N269K, Q278T, R279K, A284V, F285L, V286Y, I288T, K290E, N293D, M294I, and Q296K; an insertion of T at 290; and Delta274-275 (SI). In addition, many other mutations were recognized in the V1, V2, and V4 domains. Thus, resistance to T134 may be the consequence of amino acid substitutions in the envelope glycoprotein of X4 HIV-1. The trHIV-1(NL4-3) could not utilize CCR5 as an HIV infection coreceptor, although many amino acid substitutions were recognized. The trHIV-1(NL4-3) acquired resistance to vMIP II, which could inhibit both X4 and R5 HIV-1 infection. However, neither the ligands of CCR5, RANTES, and MIP-1alpha, nor a CCR5 low molecular antagonist, TAK-779, were able to influence the infection of trHIV-1(NL4-3). Those results indicated that alternation of coreceptor usage of trHIV-1(NL4-3) was not induced.

PubMed Disclaimer

Cited by

In vivo evolution of X4 human immunodeficiency virus type 1 variants in the natural course of infection coincides with decreasing sensitivity to CXCR4 antagonists.
Stalmeijer EH, Van Rij RP, Boeser-Nunnink B, Visser JA, Naarding MA, Schols D, Schuitemaker H. Stalmeijer EH, et al. J Virol. 2004 Mar;78(6):2722-8. doi: 10.1128/jvi.78.6.2722-2728.2004. J Virol. 2004. PMID: 14990692 Free PMC article.
The entry of entry inhibitors: a fusion of science and medicine.
Moore JP, Doms RW. Moore JP, et al. Proc Natl Acad Sci U S A. 2003 Sep 16;100(19):10598-602. doi: 10.1073/pnas.1932511100. Epub 2003 Sep 5. Proc Natl Acad Sci U S A. 2003. PMID: 12960367 Free PMC article.
Escape from human immunodeficiency virus type 1 (HIV-1) entry inhibitors.
De Feo CJ, Weiss CD. De Feo CJ, et al. Viruses. 2012 Dec;4(12):3859-911. doi: 10.3390/v4123859. Viruses. 2012. PMID: 23342377 Free PMC article. Review.
Genetic and phenotypic analyses of human immunodeficiency virus type 1 escape from a small-molecule CCR5 inhibitor.
Kuhmann SE, Pugach P, Kunstman KJ, Taylor J, Stanfield RL, Snyder A, Strizki JM, Riley J, Baroudy BM, Wilson IA, Korber BT, Wolinsky SM, Moore JP. Kuhmann SE, et al. J Virol. 2004 Mar;78(6):2790-807. doi: 10.1128/jvi.78.6.2790-2807.2004. J Virol. 2004. PMID: 14990699 Free PMC article.
Exploratory studies on development of the chemokine receptor CXCR4 antagonists toward downsizing.
Tamamura H, Tsutsumi H, Nomura W, Fujii N. Tamamura H, et al. Perspect Medicin Chem. 2008 Feb 10;2:1-9. doi: 10.4137/pmc.s422. Perspect Medicin Chem. 2008. PMID: 19787093 Free PMC article.

Biological and genetic characterization of a human immunodeficiency virus strain resistant to CXCR4 antagonist T134 - PubMed (original) (raw)